Actuate Therapeutics, Inc./$ACTU
1D1W1MYTD1Y5YMAX
About Actuate Therapeutics, Inc.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
- Ticker
- $ACTU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Fort Worth, United States
- Website
- actuatetherapeutics.com
ACTU Metrics
BasicAdvanced
$40M
-
-$0.89
0.78
-
Price and volume
Market cap
$40M
Beta
0.78
52-week high
$9.22
52-week low
$0.90
Average daily volume
333K
Financial strength
Current ratio
1.248
Quick ratio
1.163
Interest coverage (TTM)
-1,025.85%
Profitability
Management effectiveness
Return on assets (TTM)
-213.40%
Return on equity (TTM)
2,457.58%
Valuation
Price to book
40.18
Price to tangible book (TTM)
40.18
Price to free cash flow (TTM)
-1.926
Free cash flow yield (TTM)
-51.91%
Free cash flow per share (TTM)
-0.859
Growth
Earnings per share change (TTM)
-37.61%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.